EichorEICHOR
Location: Wilrijk Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Wilrijk

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · ZAS Augustinus · Pfizer · NCT07028853Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · ZAS Augustinus · Bristol-Myers Squibb · NCT07106762Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · Gasthuiszusters Antwerpen - Sint-Augustinus · European Organisation for Research and Treatment of Cancer - · NCT04498767Test-retest Reliability of sEMG to Measure Fatigue in Adolescents
NA · Universiteit Antwerpen, Department of Rehabilitation Science · Universiteit Antwerpen · NCT07161531A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · Ziekenhuis Aan de Stroom ZAS vzw · BioNTech SE · NCT07070232An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05939414Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve
NA · Sint Augustinus · Universitaire Ziekenhuizen KU Leuven · NCT04695834HIIT for Inflammatory-driven Shoulder Pain.
NA · Universiteit Antwerpen · Universiteit Antwerpen · NCT07275164OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · Clinical Trial Site · Olema Pharmaceuticals, Inc. · NCT06016738PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (
NA · Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - · European Organisation for Research and Treatment of Cancer - · NCT04790253A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Bas
NA · Sint-Augustinus Hospital (ZAS) · University Hospital, Antwerp · NCT06523374Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Phase 3 · Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus (previous GZ · European Organisation for Research and Treatment of Cancer - · NCT05815927Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases
NA · ZAS Augustinus · Cancer Research Antwerp · NCT07146074The Effects of Extracorporeal Shock Wave Therapy in Postsurgical Scars Especially After Abdominplasty and Breast Reducti
NA · Universitair Ziekenhuis · Universiteit Antwerpen · NCT06825039Boosted Compression for Lower Limb Chronic Edema
NA · University of Antwerp · Universiteit Antwerpen · NCT07708662Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases
NA · GZA · Cancer Research Antwerp · NCT06613295Differential Target Multiplexed Spinal Cord Stimulation
Phase N/A · GZA · Moens Maarten · NCT05068011Preoperative Radiation Therapy and Immediate Breast Reconstruction
NA · Ziekenhuis aan de stroom · Cancer Research Antwerp · NCT06739655Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Phase 3 · Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus (previous GZ · European Organisation for Research and Treatment of Cancer - · NCT05904119OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for
NA · Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus · European Organisation for Research and Treatment of Cancer - · NCT06462963A Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration
NA · Cochlear · NCT06805175Evaluation of Medication Tapering on the Sensitivity of the Spinal Cord Using Closed-Loop Spinal Cord Stimulation (Pilot
Phase N/A · Brai²n - ZAS Augustinus · Brai²n · NCT07502612Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
NA · ZAS Augustinus · Cliniques universitaires Saint-Luc- Université Catholique de · NCT06719440Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Phase 1 · Ziekenhuis aan de Stroom Augustinus · Amgen · NCT07531095A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · Research Site · AstraZeneca · NCT05774951Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · GZA Ziekenhuizen · Daiichi Sankyo · NCT05950945Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · Ziekenhuls aan de Stroom vzw (ZAS vzw), ZAS Augustinus · Gilead Sciences · NCT05633654Technology Supported High Intensity Training in Chronic Low Back Pain: the Techno-HIT Trial
NA · Universitair Ziekenhuis Antwerpen (UZA) · Hasselt University · NCT06491121A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced No
Phase 3 · ZAS Augustinus · Bristol-Myers Squibb · NCT07361510
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.